Navigation Links
Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
Date:10/15/2010

PITTSBURGH, Oct. 15 /PRNewswire/ -- Precision Therapeutics announced today that its President and Chief Executive Officer Sean McDonald was recognized as CEO of the Year by the Pittsburgh Technology Council.

(Photo: http://photos.prnewswire.com/prnh/20101015/NE83126 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20101015/NE83126 )

The Tech 50 award recognizes the accomplishments of 50 of southwestern Pennsylvania's most successful entrepreneurs whose innovation and creativity have been used to strategically enhance the ideals and growth of their organization as well as the community and greater region. McDonald was selected by an independent panel of technology experts and the category awards were presented on October 14, 2010, at the Hilton Downtown Pittsburgh.

Sean joined Precision in 2001 and has since dedicated his career to developing innovative technologies with the goal of helping physicians to select customized treatment to meet the individual needs of each cancer patient. He most recently led Precision to earn a first place ranking as an industry leader in the health care division in the Pittsburgh region.  Because of Sean's passion, leadership and vision, Precision Therapeutics remains at the forefront of personalized diagnostics and research for individualized cancer therapy, with nearly 32,000 patient specimens sent for ChemoFx® testing and 18 active clinical trials.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy.  Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician.

For more information, please visit www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Applied Precision Installs New DeltaVision
2. OMX® Super-Resolution Imaging System in the Light Microscopy Imaging Center at Indiana University
3. Pinpoint precision: Delivering a biochemical payload to 1 cell
4. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
5. Stretching single molecules allows precision studies of interacting electrons
6. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
7. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
8. New statistical technique improves precision of nanotechnology data
9. Precision Stability Storage Announces Upcoming Expansion
10. NISTs LIDAR may offer peerless precision in remote measurements
11. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:5/6/2017)... 5, 2017 RAM Group , ... new breakthrough in biometric authentication based on a ... properties to perform biometric authentication. These new sensors are ... created by Ram Group and its partners. This sensor ... supply chains and security. Ram Group is a ...
Breaking Biology News(10 mins):